Nested Therapeutics

Nested Therapeutics is a Cambridge, Massachusetts clinical-stage biotech building small-molecule precision oncology drugs that go after cancer driver mutations long written off as undruggable. Founded in 2021 and launched publicly in 2022 with $125M, the company pairs structural biology, computational biophysics and chemistry to find hidden, druggable pockets in cancer's most stubborn targets. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue for RAS/MAPK-driven solid tumors, now in Phase 1 with early clinical activity reported at AACR 2026.